tbuckley/cabot-search huggingface dataset:
Abstract 10014: Prognostic Value of the Combination of Aortic Pulsatility Index and Fibrosis-4 Index in Patients Admitted for Acute Decompensated Heart Failure
Authors: Takahisa Yamada, Tetsuya Watanabe, Takashi Morita, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Jun Nakamura, Kiyomi Kayama, KUMPEI UEDA, Daisuke Sakamoto, Yuto Tamura, Takeshi Fujita, Takehiro Kogame, Keisuke Nishigaki, Yuto Fukuda, Yuki Kokubu, Masatake Fukunami
Journal: Circulation (2021)

Backgrounds: Aortic pulsatility index (API), calculated as (systolic - diastolic blood pressure)/pulmonary capillary wedge pressure, is a novel hemodynamic measurement representing cardiac filling pressures, and contractility and has been shown to be associated with adverse clinical outcome in patients with advanced heart failure (HF). On the other hand, cardiohepatic interactions have been a focus of attention in HF, and liver dysfunction in HF patients is caused by liver congestion, which is related to liver stiffness. It has been recently reported that liver stiffness assessed by non-invasive fibrosis marker such as Fibrosis-4(FIB4) index predicts the poor outcome in HF patients. However, there is no information available on the prognostic value of the combination of API and FIB4 index in patients with acute decompensated heart failure (ADHF). Methods and Results: We studied 238 patients admitted for ADHF, who underwent right heart catheterization at the admission and were discharged with survival. API was obtained at the admission. FIB4 index was calculated by the formula: age(yrs) х AST[U/L]/(platelets [10 9 /L] х (ALT[U/L]) 1/2 ). FIB4 index &gt;2.67 was defined as abnormal, as previously reported. During a follow up period of 5.2±4.4 yrs, 58 patients had cardiovascular death (CVD). At multivariate Cox analysis, API and FIB4 index were significantly associated with CVD, independently of serum creatinine level and prior heart failure hospitalization, after the adjustment with hemoglobin and serum albumin levels. The patients with both lower API ≤1.905 (AUC 0.665[0.584-0.546]) and abnormal FIB4 index had a significantly increased risk of CVD than those with either lower API or abnormal FIB4 index and none of them (50% vs 23% vs 16%, p=0.0003, respectively). Conclusion: The combination of API and FIB4 index might be useful for stratifying ADHF patients at higher risk for CVD.
Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy
Authors: Kyung Hee Chang, Tomasz Zal, Mahesh Basyal, Lauren Ostermann, Muharrem Muftuoglu, Po Yee Mak, Yannan Jia, Wenjing Tao, Malgorzata Anna Zal, William E. Fogler, John L. Magnani, Weiguo Zhang, Bing Z Carter, Michael Andreeff
Journal: Blood (2021)
COVID‐19 vaccines tolerated in patients with paclitaxel and docetaxel allergy
Authors: Aleena Banerji, Anna R. Wolfson, Lacey B. Robinson, Aubree E. McMahon, Amelia S. Cogan, Rebecca R. Saff, Kimberly G. Blumenthal
Journal: Allergy (2021)

Dr. Blumenthal receives grant support from the NIH/NIAID K01 AI12563 and the Massachusetts General Hospital Department of Medicine Transformative Scholar Program.
A Real-World Study of Pre-Post Annualized Bleed Rates and All Cause Costs Among Non-Inhibitor Patients with Hemophilia a Switching from FVIII Prophylaxis to Emicizumab
Authors: Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Megha Dayma, Michael Bullano
Journal: Blood (2021)
Abstract 10980: Long-Term Clinical Outcomes of Continuous Statin Therapy in Patients with Deferral of Coronary Intervention Based on Fractional Flow Reserve
Authors: Masanobu Ishii, Kenshi Yamanaga, Yasuhiro Otsuka, Kenichi Tsujita, Shoichi Kuramitsu, Hiroaki Takashima, Hitoshi Matsuo, HIROYOSHI YOKOI, Nobuhiro Tanaka
Journal: Circulation (2021)

Background: The optimal medication therapy for patients with angiographically intermediate coronary artery stenosis in whom revascularization was deferred by fractional flow reserve (FFR) remains to be fully established. The aim of this study was to investigate the long-term outcomes of continuous statin therapy in those patients. Methods: This sub-analysis of the J-CONFIRM registry (Long-Term Outcomes of Japanese Patients With Deferral of Coronary Intervention Based on Fractional Flow Reserve in Multicenter Registry) included 1113 patients who have completed 2-year follow-up and were divided into 2 groups according to continuation of statin treatment. Landmark analyses were performed that compared treatments during the follow-up period between 2 years and 5 years to assess the composite endpoints, including target vessel failure and non-cardiac death in the Cox proportional hazard regression with mixed effects account for institutional variety and inverse probability of treatment weighting (IPTW) analyses. Target vessel failure was defined as cardiac death, target-vessel related myocardial infarction, and clinically driven target vessel revascularization. Results: By the start of the landmark at 2-year, 681 (61.2%) patients had continued the statin, whereas 432 (38.8%) had not continued. Composite endpoint was observed in 68 (10.0%) patients with continuous statin and 54 (12.5%) in those with discontinuous statin. The multivariate mixed effects Cox regression model and IPTW adjusted for baseline characteristics, comorbidity, FFR value, culprit vessel, and medication revealed that the continuous statin was not associated with a low risk of composite endpoint (HR: 0.81, 95% CI: 0.54 to 1.21, HR: 0.81, 95% CI: 0.62 to 1.05, respectively). Subgroup analysis showed significant interaction between sex, prior myocardial infarction (pMI) and the continuous statin, indicating that the continuous statin therapy was associated with a low risk of composite endpoint in male (HR: 0.62, 95% CI: 0.41, 0.93) and patients with pMI (HR: 0.42, 95% CI 0.22, 0.82). Conclusions: The present study showed that continuous statin therapy was not associated with better long-term outcomes in patients with deferral of coronary intervention based on FFR.
69 Immunophenotyping of TCR and BCR clonotypes
Authors: Alex Chenchik, Michael Makhanov, Russell Darst, Tianbing Liu, Lester Kobzik
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background T-cell receptor (TCR) and B-cell receptor (BCR) repertoire profiling holds great potential for understanding disease mechanisms and for the development of new therapeutics in infectious diseases, autoimmunity and in immuno-oncology. However, this potential could be greatly improved by combining information about receptor clonotypes with immuno-phenotypes of T and B cells. Methods To facilitate these studies, we developed a novel technology for combined profiling of all human TCR and BCR variable regions and phenotypic characterization of immune cells in bulk and at the single-cell level in PBMC and immune cell fraction samples. The developed TCR/BCR Immunophenotyping method involves multiplex RT-PCR amplification and sequencing of CDR3 regions of TCR and BCR genes and a set of the most informative T- and B-cell phenotyping genes. Bioinformatics analysis of NGS data allows profiling of TCR/BCR clonotypes, and identification of major immune cell subtypes and their activation status. Results Data will be presented showing how combined TCR/BCR clonotype analysis combined with targeted expression profiling of immune cells can be applied for large-scale discovery of novel cell typing and activation biomarkers in several immune-responsive model systems. Conclusions Preliminary studies demonstrate the assay has unparalleled throughput, sensitivity, and improved cost-effectiveness for high-throughput immunity biomarker discovery applications.
291 Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity
Authors: Coline Couillault, Anupallavi Srinivasamani, Shweta Hedge, Qinying Liu, Ashwin Jaiswal, Dongxing Zha, Michael Curran
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Inhibition of T cell activation and effector function via engagement of the co-inhibitory receptor PD-1 is a critical mechanism enabling tumors to evade host immunity. The two ligands for PD-1, PD-L1 and PD-L2, can be expressed by a variety of immunosuppressive stromal cells, particularly of the myeloid lineage, endothelial cells, and by tumors themselves. In addition to PD-1, PD-L1 engages B7-1 in an additional co-inhibitory interaction. Blocking only PD-1 or only PD-L1 thus does not relieve all inhibitory components of this pathway. We hypothesized that bispecific antibodies blocking both PD-L1 and PD-L2 could more fully restore tumor-specific T cell activation and potentiate anti-cancer immunotherapy. Furthermore, we speculated that enhancing the cytotoxic effector function of these antibodies might further enhance their efficacy through the depletion of tumor cells and supportive stroma. Methods We investigated the capacity of monoclonal antibodies capable of bivalent binding to both PD-L1 and PD-L2 to restore the function of PD-1-suppressed T cells in vitro. To assess the in vivo therapeutic efficiency of bispecific PD-Ligand antibodies with ADCC capacities, mouse IgG2a and modified human IgG1 versions were generated. We assessed their ADCC activity in vitro using a bioluminescent reporter assay, and their therapeutic efficiency in vivo in syngeneic or human-cell derived tumors. Results The bispecific antibodies we generated restore the function of PD-1-suppressed T cells in vitro with equivalent efficiency to the FDA approved PD-1 antibody Pembrolizumab. Moreover, our modified human bispecific antibodies lead to significantly higher FcγRIIa activation than FDA-approved clinical human IgG1 PD-L1 antibodies in vitro. In vivo, ADCC-capable PD-Ligand bispecific antibodies suppress the growth of U2940 lymphoma in immunodeficient mice more efficiently than Rituximab, and in a syngeneic model of PD-L1/PD-L2 double positive colon carcinoma, these antibodies demonstrate superiority to PD-1 blocking antibodies to limit tumor growth and increase survival. Furthermore, treatment with our bispecific antibodies increases T cell proliferation and cytotoxicity and reduces density of immunosuppressive myeloid stroma in vivo. Conclusions ADCC-capable PD-Ligand bispecific antibodies display higher therapeutic potential than existing anti-PD-1 antibodies and represent a new class of PD-1 pathway therapeutics with significant potential for the treatment of a variety of human cancers. Acknowledgements I would like to thank Anupallavi Srinivasamani, PhD student in Michael Curran’s lab, who performed a considerable amount of the work on this project before I joined.
Disease Characteristics of AML Patients with Germline <i>DDX41</i> Variants
Authors: Jennie Vagher, Shobi Venkatachalam, Peng Li, Julie D. Asch, Bryan D. Huber, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Luke Maese, Charles J. Parker, Srinivas K. Tantravahi
Journal: Blood (2021)
An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies
Authors: Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, Yesid Alvarado, Franck E. Nicolini, Krishnakumar Rathnam, Navin Khattry, Jane F Apperley, Michael W. Deininger, Hugues de Lavallade, Aude Charbonnier, Nikki Granacher, Carlo Gambacorti-Passerini, Alessandro Lucchesi, Michael J. Mauro, Peter Vandenberghe, Gregor Verhoef, Andrew R. Whiteley, Arijit Nag, Vivek S Radhakrishnan, Shashikant Apte, Siu-Long Yao, Sandeep Inamdar, Jayasree Sreenivasan, Ruchika Irene Dillu, Geetanjali Chimote
Journal: Blood (2021)
Abstract 10708: Cannabidiol Loaded Nanoparticles Exhibit an Anti-Fibrotic Effect in a Mouse Model of Non-Ischemic Heart Failure
Authors: Muthu Kumar Krishnamoorthi, Forughalsadat Sanaee, Afsaneh Lavasanifar, Anthony Bolton, Keith Youker, Arvind Bhimaraj
Journal: Circulation (2021)

Introduction: Cannabidiol (CBD) is being studied in a spectrum of ailments including cardiovascular disorders. It is also clinically prescribed for certain diseases. However, the hydrophobicity of CBD has been reported to contribute to low oral bioavailability. Here we use a polymeric nanoparticle formulation of CBD (nCBD) to overcome this limitation and evaluate its potential in heart failure (HF). Methods: HF was induced in 3-month old C57BL/6J mice with drinking water containing 1% NaCl and 0.3 mg/mL of L-NAME. After 1-week, subcutaneous osmotic pumps were implanted to deliver angiotensin-II at a rate of 0.7mg/kg/day for 4 weeks. nCBD was prepared using co-solvent evaporation of poly(ethylene oxide)-poly(α-benzyl carboxylate-ε-caprolactone) (PEO-b-PBCL) and pharmaceutical-grade CBD. nCBD (1 mg/kg) was injected 2 times per week subcutaneously in HF mice and Control mice. At week 5, Masson’s trichrome and H &amp; E staining was performed to evaluate severity of fibrosis and cardiomyocyte (CM) size respectively using Cell Sense Dimension Software from Olympus. Results: PEO-b-PBCL nanoparticles localized in both interstitial and replacement fibrotic regions in the heart of our HF mice. HF mice with nCBD treatment displayed less fibrosis when compared to HF mice without treatment as shown in a representative image of fibrosis staining (Figure A). Histological quantification depicted that fibrosis area was higher in HF mice and was significantly (p&lt;0.0001) reduced in HF mice exposed to nCBD (Figure B). Treatment of HF mice with nCBD also influenced CM size. Normal mice had a mean CM size of 12.33±2.07 μm. This increased to 21.17±2.88 μm in HF mice without treatment. However, nCBD treatment significantly (p&lt;0.0001) decreased CM size to a mean value 14.76±2.71 μm (Figure C). Conclusion: Our results show that nCBD has an anti-fibrotic and anti-hypertrophic effect in a mouse model of non-ischemic heart failure.
Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)
Authors: Melanie T Rebechi, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, James S. Blachly, Shelley Orwick, William Blum, Bayard L. Powell, Geoffrey L. Uy, Richard M. Stone, John C. Byrd, Electra D. Paskett, Jesse Plascak, Ann-Kathrin Eisfeld
Journal: Blood (2021)
Patient-focused pathogen genetic counselling—has the time come?
Authors: Angeline S Ferdinand, Jane S Hocking, Justin T. Denholm, Benjamin P. Howden, Deborah A. Williamson
Journal: Genome Medicine (2021)

Abstract Ensuring accordance with principles of healthcare ethics requires improved communication of pathogen genomic data. This could include educating healthcare professionals in communicating pathogen genomic information to individuals, developing ethical frameworks for reporting pathogen genomic results to individuals, responsible media reporting guidelines, and counselling for individuals (‘pathogen genetic counselling’).
Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group
Authors: Lionel Ades, Sophie Dimicoli-Salazar, Marie Sebert, Thomas Cluzeau, Aspasia Stamatoulas Bastard, Kamel Laribi, Gaelle Fossard, Raphael Itzykson, Odile Beyne Rauzy, Alice Garnier, Silke Gloaguen, Norbert Vey, Caroline Le Jeune, Aristoteles Giagounidis, Emmanuel Gyan, Baptiste Perard, Sylvain Thepot, Mario Ojeda, Fatiha Chermat, Kristell Desseaux, Emmanuelle Clappier, Sylvie Chevret, Uwe Platzbecker, Pierre Fenaux
Journal: Blood (2021)
Treatment Patterns and Survival Outcomes of Patients with Acute Myeloid Leukemia Who Achieved Remission in the Connect ® Myeloid Disease Registry
Authors: Gail J. Roboz, Mehrdad Abedi, Michael A. Thompson, Mikkael A. Sekeres, Daniel A. Pollyea, Karen Seiter, Edward Yu, Pavel Kiselev, Michelle Little, Irina Fernandez, Irene S. DeGutis, Harry P. Erba
Journal: Blood (2021)
Fat shaming is stopping doctors from helping overweight patients—here’s what medical students can do about it
Authors: Triya Chakravorty
Journal: BMJ (2021)

Fat shaming is stopping doctors from helping overweight patients-here's what medical students can do about it Obesity stigma can harm people's health and is even more damaging when it comes from healthcare professionals, says Triya Chakravorty Triya Chakravorty sixth year medical student People who are obese are highly stigmatised in society and face many forms of discrimination due to their weight. 1This weight bias translates into inequalities faced in healthcare, employment, and education. 1 In a healthcare setting, negative attitudes held by healthcare professionals will make patients feel stigmatised and reluctant to access healthcare services, further damaging their long term health.The social stigma faced by overweight healthcare professionals will also have an impact on their own confidence and ability to deliver healthcare advice.
Basic and Translational Research in Cardiac Repair and Regeneration
Authors: Jianyi Zhang, Roberto Bolli, Daniel J. Garry, Eduardo Marbán, Philippe Menasché, Wolfram-Hubertus Zimmermann, Timothy J. Kamp, Joseph C. Wu, Victor J. Dzau
Journal: Journal of the American College of Cardiology (2021)

This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors' own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.
The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib
Authors: Arthur Gomes Oliveira Braga, Katia B Pagnano, Marina Dal'Bó Pelegrini Campioni, Ana Beatriz P Lopez, Konradin Metze, Gislaine B O Duarte, Irene Lorand-Metze
Journal: Blood (2021)
Abstract 9496: 30-days Mortality Risk in the Patients Following Atrial Fibrillation Ablation in the Entire Nation of Poland: An 8-Year Analysis from National Health Fund of Poland
Authors: Michal Orczykowski, Marcin Kowalski, Valay K. Parikh, Piotr Urbanek, Bodalski Robert, Pawel Derejko, Grzegorz Warminski, Andrzej Hasiec, Krzysztof Dubowski, Andrzej Glowniak, Radoslaw Sierpinski, Filip Urbanski, Maria Bilinska, Lukasz Szumowski
Journal: Circulation (2021)

Introduction: Atrial fibrillation (AF) is the most common sustained arrhythmia. Catheter Ablation (CA) is considered as a first-line therapy for AF. The risk of 30-days all-cause mortality associated with CA for AF may be underestimated in clinical trials and selected-cohort studies due to selection bias. Hypothesis: We evaluated 30-days all-cause mortality associated with CA for AF in the entire country of Poland Methods: The data was collected from the Polish national healthcare service (the National Health Fund of Poland). In the Polish health system covers &gt;99% of CA for AF for the entire country. All consecutive CA in patients &gt;18 years of age, between Jan 2012 and Dec 2019 were included in the study. CA for AF was identified by unique codes assigned to pulmonary vein isolation and CA for AF. The mortality rate was calculated for each age group. Results: During 8-year follow-up period, 31,214 CA of AF were performed in 26,767 patients. 9315 (34.8%) patients were female. 13758 (51.4%) patients had Cryoballoon ablation. Thirty-two deaths (0.1%) within 30-days of the CA were identified. The mortality rate was low and similar in each age group except in the oldest age group (age&gt;80). The oldest age group had significantly higher 30-days mortality than any other age group. (Figure). Conclusions: In the large, consecutive patient population in the entire country of Poland, 30- days mortality following AF ablation for past 8-years remains low. In real-world clinical practice patients over the age of 80 have higher risk of 30-day all-cause mortality than any other age group found over last seven years. Systematic review is needed to further risk-stratify these findings.
Protein Disulphide Isomerase 6 (PDIA6) Attenuates Platelet Endoplasmic Reticulum Stress and Secretion in a Mouse Model
Authors: Freda H. Passam, Angelina Lay, Alexander Dupuy, Jessica Tieng, Lejla Hagimola, Jessica Maclean, Marc Ellis, Philip Hogg
Journal: Blood (2021)
Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study
Authors: Andre Manfred Willasch, Christina Peters, Adriana Balduzzi, Jean-Hugues Dalle, Marco Zecca, Amal Al-Seraihy, Franco Locatelli, Yves Bertrand, Stephen Robinson, Tracey OBrien, Amos Toren, Dragana S. Vujic, Jacques-Olivier Bay, Charlotte Jubert, Maura Faraci, Fanny Rialland, Vassiliki Kitra-Roussou, Gerard Michel, Mariacristina Menconi, Franca Fagioli, Ottavio Ziino, Mikael Sundin, Cecile Pochon, Paul Veys, Jose Maria Moraleda, Alessandra Biffi, Arnaud Dalissier, Selim Corbacioglu, Maud Ngoya, Jacques-Emmanuel Galimard, Peter Bader
Journal: Blood (2021)
Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study
Authors: Geoffrey Shouse, Andy Kaempf, David Yashar, Audrey M. Sigmund, Gordon Smilnak, Steven M. Bair, Agrima Mian, Lindsey Fitzgerald, Amneet Bajwa, Samantha Jaglowski, Neil Bailey, Mazyar Shadman, Krish Patel, Deborah M. Stephens, Manali Kamdar, Brian T. Hill, Jordan Gauthier, Reem Karmali, Adam S Kittai, Alexey V. Danilov
Journal: Blood (2021)
Magnetic mediators for ultrasound theranostics
Authors: Arkadiusz Józefczak, Katarzyna Kaczmarek, Rafał Bielas
Journal: Theranostics (2021)

The theranostics paradigm is based on the concept of combining therapeutic and diagnostic modalities into one platform to improve the effectiveness of treatment.Combinations of multiple modalities provide numerous medical advantages and are enabled by nano-and micron-sized mediators.Here we review recent advancements in the field of ultrasound theranostics and the use of magnetic materials as mediators.Several subdisciplines are described in detail, including controlled drug delivery and release, ultrasound hyperthermia, magneto-ultrasonic heating, sonodynamic therapy, magnetoacoustic imaging, ultrasonic wave generation by magnetic fields, and ultrasound tomography.The continuous progress and improvement in theranostic materials, methods, and physical computing models have created undeniable possibilities for the development of new approaches.We discuss the prospects of ultrasound theranostics and possible expansions of other studies to the theranostic context.
Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial
Authors: Vinod A. Pullarkat, Mark Levis, Gabriel N. Mannis, Stephen A Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Harry P. Erba
Journal: Blood (2021)
Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma
Authors: Gilles Salles, Stephen J. Schuster, Martin H. Dreyling, Luca Fischer, John Kuruvilla, Piers EM Patten, Bastian Von Tresckow, Sonali M. Smith, Ana Isabel Jiminez Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, C Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Yucai Wang, Brian K. Link
Journal: Blood (2021)